SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Navidea Biopharmaceuticals, Inc. – ‘8-A12B’ on 2/8/11

On:  Tuesday, 2/8/11, at 9:58am ET   ·   Accession #:  1144204-11-6496   ·   File #:  1-35076

Previous ‘8-A12B’:  None   ·   Next & Latest:  ‘8-A12B’ on 4/12/22   ·   16 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 2/08/11  Navidea Biopharmaceuticals, Inc.  8-A12B                 1:24K                                    Vintage/FA

Registration of a Class of Securities   —   Form 8-A
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-A12B      Registration of a Class of Securities               HTML     20K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  Unassociated Document  
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-A
 
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
 
NEOPROBE CORPORATION
(Exact name of registrant as specified in its charter)
 
Delaware
 
31-1080091
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
     
425 Metro Place North, Suite 300, Dublin, Ohio
 
43017-1367
(Address of principal executive offices)
 
(Zip Code)
 
Title of each class
to be so registered
 
Name of each exchange on which
each class is to be registered
     
Common Stock, par value $.001 per share
 
NYSE Amex
 
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. x
 
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. o
 
 
 

 

Item 1.  Description of Registrant’s Securities to be Registered.

Incorporated by reference to the registrant’s Rule 424(b)(5) Prospectus Supplement filed on November 9, 2010, Registration File No. 333-168485, under the caption “Description of Capital Stock—Common Stock.”

Item 2.  Exhibits.
 
Exhibit
Number
 
Footnote
 
Exhibit Description
         
4.1
 
(a)
 
         
4.2
 
(b)
 
Amended and Restated By-Laws dated July 21, 1993, as amended July 18, 1995, May 30, 1996 and July 26, 2007.

(a)  Incorporated by reference to Exhibit 4.1 filed on August 3, 2010, with the registrant’s Registration Statement on Form S-3, Registration File No. 333-168485.

(b) Incorporated by reference to Exhibit 3.2 filed on August 3, 2007, with the registrant’s Current Report on Form 8-K.

 
 

 
 
SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
 
 
NEOPROBE CORPORATION
 
     
     
 
 
Brent L. Larson, Senior Vice President, Chief Financial
 
Officer, Treasurer and Secretary
 

 
 

 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-A12B’ Filing    Date    Other Filings
Filed on:2/8/11
11/9/10424B5
8/3/10S-3
8/3/078-K
7/26/073,  4,  8-K,  DEF 14A
11/20/06
6/22/05
7/27/04DEF 14A,  PRE 14A
6/13/03
5/9/00
3/17/99
6/3/96
5/30/96
7/18/95
6/27/94
2/18/94
7/21/93
 List all Filings 


16 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/29/23  Navidea Biopharmaceuticals, Inc.  S-3         8/28/23    5:446K                                   RDG Filings/FA
 4/28/23  Navidea Biopharmaceuticals, Inc.  424B5                  1:505K                                   RDG Filings/FA
12/22/22  Navidea Biopharmaceuticals, Inc.  S-8        12/22/22    5:233K                                   RDG Filings/FA
 8/04/22  Navidea Biopharmaceuticals, Inc.  424B4                  1:1M                                     RDG Filings/FA
 8/02/22  Navidea Biopharmaceuticals, Inc.  S-1/A                 15:1.9M                                   RDG Filings/FA
 7/20/22  Navidea Biopharmaceuticals, Inc.  S-1/A                 13:1.6M                                   RDG Filings/FA
 7/01/22  Navidea Biopharmaceuticals, Inc.  S-1/A                  2:1M                                     RDG Filings/FA
 2/14/22  Navidea Biopharmaceuticals, Inc.  S-1         2/11/22    3:944K                                   RDG Filings/FA
 5/24/21  Navidea Biopharmaceuticals, Inc.  424B3                  1:190K                                   RDG Filings/FA
 5/13/21  Navidea Biopharmaceuticals, Inc.  S-1                    3:378K                                   RDG Filings/FA
 2/08/21  Navidea Biopharmaceuticals, Inc.  S-3                    4:908K                                   RDG Filings/FA
11/13/20  Navidea Biopharmaceuticals, Inc.  S-8        11/13/20    4:1.7M                                   RDG Filings/FA
 9/02/20  Navidea Biopharmaceuticals, Inc.  424B5                  1:511K                                   RDG Filings/FA
 9/02/20  Navidea Biopharmaceuticals, Inc.  424B5                  1:546K                                   RDG Filings/FA
 8/25/20  Navidea Biopharmaceuticals, Inc.  S-3                    4:401K                                   RDG Filings/FA
 8/11/20  Navidea Biopharmaceuticals, Inc.  424B5                  1:576K                                   RDG Filings/FA
Top
Filing Submission 0001144204-11-006496   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 15, 1:54:27.1am ET